Current Evaluation of Lymphoedema and Assessment by Lymphoscintigraphy of the Effect of a Micronized Flavonoid Fraction (Daflon 500 mg) in the Treatment of Upper Limb Lymphoedema

1994 ◽  
Vol 9 (1_suppl) ◽  
pp. 26-29 ◽  
Author(s):  
A. P. Pecking ◽  
P. Rambert
Keyword(s):  
Breast Cancer ◽  
Upper Limb ◽  
Previous Treatment ◽  
University Hospital ◽  
Limb Volume ◽  
Flavonoid Fraction ◽  
Radionuclide Lymphoscintigraphy ◽  
Hospital Outpatients ◽  
Open Pilot ◽  
Volume Decrease

Objective: To assess the effect of Daflon 500 mg on upper lymphoedema occurring after conventional treatment of breast cancer. Design: Open, pilot, single centre trial. Setting: Hospital outpatients attending a University Hospital. Patients: Ten female patients (aged 44–64 years) whose previous treatment for breast cancer was followed by upper limb lymphoedema (mean (SD) time delay = 17±7 months). Interventions: Oral administration of a daily dose of two tablets of Daflon 500 mg for 6 months. Main outcome measures: Symptoms, affected upper limb volume and parameters of radionuclide lymphoscintigraphy using technetium-99m. Results: All patients experienced improvement of symptoms and limb volume (mean volume decrease of the swollen limb: 6.80%). Functional parameters assessed with scintigraphy were significantly improved (half-life: 147.4 (14.9) to 144.1 (14.9) min, p < 0.01; clearance of the colloid: 25.9 (2.5) to 28.3 (2.8) <l/min, p < 0.05; lymphatic speed of the colloid: 7.7 (0.3) to 8.0 (0.2) cm/min, p < 0.05). Conclusion: These preliminary results suggest that this therapy is effective for the treatment of lymphoedema.

scholarly journals COMPREHENSIVE PHYSICAL ANTIEDEMATOUS THERAPY IN THE TREATMENT OF UPPER LIMB LYMPHOSTASIS

2018 ◽  
Vol 23 (2) ◽  
pp. 82-83
Author(s):  
G. K Kurbatov ◽  
Alexander F. Lazarev ◽  
A. P Bochkarev
Keyword(s):  
Breast Cancer ◽  
Upper Limb ◽  
Stage I ◽  
Comprehensive Treatment ◽  
Complete Regression ◽  
Complex Treatment ◽  
Radical Treatment ◽  
The Difference ◽  
Volume Decrease

The aim of the study was to decrease or to eliminate upper limb lymphostasis with the use of comprehensive physical antiedematous therapy (CPhAT) in patients after the radical treatment of breast cancer. Material and methods. The work was based on data about 30 patients. There are presented the CPhAT technique, the results of the treatment and ways to evaluate the effectiveness of the treatment. To evaluate the results of the treatment, we used the technique developed by ourselves, consisting in immersing first the healthy upper limb, then the affected upper limb in a vessel with a disinfectant. The degree of edema (lymphostasis) and the evaluation of the effectiveness of treatment were determined according to the difference of the displaced fluid (patent for invention No. 2169358). The method is ultra-precise in comparison with a centimeter tape. Results. The developed comprehensive treatment of the upper limb lymphostasis allows achieving the complete regression of stage I-II edema, and volume decrease of III-IV stage edema in 83% patients. Using the developed complex treatment of edema of the upper limb prevents its recurrence in the next three years in 90% patients.

scholarly journals Effect of Acute Exercise on Upper-Limb Volume in Breast Cancer Survivors: A Pilot Study

2009 ◽  
Vol 61 (4) ◽  
pp. 244-251 ◽  
Author(s):  
Margaret L. McNeely ◽  
Kristin L. Campbell ◽  
Kerry S. Courneya ◽  
John R. Mackey
Keyword(s):  
Breast Cancer ◽  
Pilot Study ◽  
Cancer Survivors ◽  
Upper Limb ◽  
Breast Cancer Survivors ◽  
Acute Exercise ◽  
Limb Volume

Correlation Between Upper Limb Volume and Arterial and Venous Blood Flow Velocity in Lymphedema Secondary to Breast Cancer Treatment

2017 ◽  
Vol 40 (4) ◽  
pp. 241-245 ◽  
Author(s):  
Monique Silva Rezende ◽  
Ana Luiza Marsengo ◽  
Amanda Apolinário ◽  
Vânia Tie Koga Ferreira ◽  
Elaine Caldeira de Oliveira Guirro
Keyword(s):  
Breast Cancer ◽  
Blood Flow ◽  
Cancer Treatment ◽  
Flow Velocity ◽  
Upper Limb ◽  
Blood Flow Velocity ◽  
Venous Blood ◽  
Breast Cancer Treatment ◽  
Venous Blood Flow ◽  
Limb Volume

scholarly journals Electronic Moxibustion for Breast Cancer-Related Lymphedema: A Pilot Clinical Trial

2020 ◽  
Vol 19 ◽  
pp. 153473542096285
Author(s):  
Kyungsun Han ◽  
Ojin Kwon ◽  
Hyo-Ju Park ◽  
Ae-Ran Kim ◽  
Boram Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Range Of Motion ◽  
Upper Limb ◽  
Life Questionnaire ◽  
Breast Cancer Patients ◽  
Shoulder Range Of Motion ◽  
Breast Cancer Related Lymphedema ◽  
Shoulder Range

This is a preliminary study to investigate the feasibility of electronic moxibustion in breast cancer patients with upper limb lymphedema. As current treatment options for lymphedema are unsatisfactory and time consuming, there have been attempts to manage symptoms using integrative treatments. Electronic moxibustion was developed to compensate for the shortcomings of conventional moxibustion and is widely used in clinical practice. However, there have been no studies on using electronic moxibustion in breast cancer-related lymphedema. To investigate the feasibility of electronic moxibustion in treating breast cancer-related lymphedema, this study included subjects who completed primary cancer treatment at least 6 months ago and had more than 10 mm difference in arm circumference of upper limbs. All subjects were assigned to the treatment group. Subjects were treated with 16 sessions (30 minutes/session) of electronic moxibustion for 8 weeks followed by 4 weeks of follow-up. For outcome measures, upper limb circumferences, shoulder range of motion, bioimpedance analysis, and quality of life questionnaire were assessed. All 10 subjects completed the study. The effective index showed 38.21% reduction after treatment ( P = .0098) and 29.35% ( P = .0039) after 4 weeks of follow-up compared to the baseline. The reduction of lymphedema was most prominent at 10 cm above the elbow crease, where the mean reduction of circumference difference was 7.5 mm ( P = .0430) and continued to improve after treatment (mean reduction of 8.3 mm, P = .0156). There was significant improvement in shoulder range of motion only in flexion and internal rotation at week 9. There were 7 adverse events, and most were irrelevant to the treatment. Only 1 participant had a mild burn on the acupuncture point. Here, we demonstrate for the first time that electronic moxibustion treatment is a feasible treatment for breast cancer-related lymphedema. Electronic moxibustion may reduce differences in upper limb circumference and improve shoulder range of motion. A future comparative clinical trial is needed to confirm the clinical efficacy of this treatment.

scholarly journals Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases

Breast Care ◽  
2021 ◽  
pp. 1-6
Author(s):  
Karin Kast ◽  
Julia Häfner ◽  
Evelin Schröck ◽  
Arne Jahn ◽  
Carmen Werner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Risk ◽  
Genetic Counselling ◽  
Primary Breast Cancer ◽  
Ductal Carcinoma ◽  
Familial Cancer ◽  
University Hospital ◽  
Tumor Board ◽  
Newly Diagnosed ◽  
Familial Cancer Risk

<b><i>Background:</i></b> In clinical routine, not every patient who is offered genetic counselling and diagnostics in order to investigate a familial cancer risk predisposition opts for it. Little is known about acceptance of counselling and testing in newly diagnosed breast cancer cases in Germany. <b><i>Methods:</i></b> All primary breast cancer cases and patients with DCIS (ductal carcinoma in situ) treated at the University Hospital of Dresden between 2016 and 2019 were included. The number of tumor board recommendations for genetic counselling on the basis of the GC-HBOC risk criteria was recorded. Acceptance was analyzed by number of cases with counselling in the GC-HBOC-Center Dresden. <b><i>Results:</i></b> Of 996 primary breast cancer and DCIS cases, 262 (26.3%) were eligible for genetic counselling. Recommendation for genetic counselling was accepted by 64.1% (168/262). Of these 90.5% (152/168) opted for molecular genetic analysis. The acceptance rate for counselling increased between 2016 and 2019 from 58.3 to 72.6%. Altogether, 20.4% (31/152) patients were found to carry a pathogenic variant in the breast cancer genes <i>BRCA1</i> or <i>BRCA2</i>. <b><i>Conclusion:</i></b> Acceptance of recommendation is increasing as clinical consequences augment. Optimization in providing information about hereditary cancer risk and in accessibility of counselling and testing is required to further improve acceptance of recommendation.

Sign in / Sign up

Export Citation Format

Share Document